Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Core Insights - Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in clinical development for autoimmune diseases [1][2][4] - Dr. Zuraw previously led the development of telitacicept at RemeGen, achieving multiple regulatory approvals in China for systemic lupus erythematosus, generalized myasthenia gravis, and rheumatoid arthritis [2][3] - Vor Bio aims to advance telitacicept through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions globally [5] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [5] - The company is working on telitacicept, a novel dual-target fusion protein, to address serious conditions driven by autoantibodies [5] Leadership Experience - Dr. Zuraw has held senior roles at various pharmaceutical companies, including Janssen, Teva, and Biogen, where she led global clinical development programs [4] - She has been instrumental in achieving FDA approvals for therapies in multiple therapeutic areas, showcasing her capability in managing complex clinical trials [4]